Kairos Pharma, LTD. Logo

Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):
US48301N1046
LEI:
Country:
United States of America
Address:
2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America
PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America
PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea
041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.